News

Fourth quarter 2010 R&D expenses decreased to $23.6m from $31.6m in last year, driven by lower development costs associated with the peramivir and forodesine clinical programs. Total revenues

The HQM Reporting Module is a proprietary, clinical data repository which does the automated registry reporting of clinical outcomes, and quality measure data for pay-for-performance (P4P) programs. The

Anacor will receive a $7m upfront payment from Medicis and will be primarily responsible for discovering and conducting early development of product candidates which utilize Anacor’s proprietary boron

Initially, the PKD Foundation will help Intellikine to evaluate the drug candidates using pre-clinical models of the disease. PKD Foundation chief scientific officer Jill Panetta said Intellikine is

The trial aims to assess the safety, tolerability and pharmacokinetics in healthy volunteers. TMC649128, a nucleoside NS5B polymerase inhibitor with an exciting pre-clinical profile, is indicated for the

Covidien‘s FTS is a generic alternative to the branded Duragesic patch. FTS, a Class II controlled substance, is an opioid analgesic indicated in opioid-tolerant patients for management of

Colesevelam, an oral bile acid sequestrant for hypercholesterolemia, is developed by Genzyme and marketed in the US by Daiichi Sankyo under the brand name WelChol and elsewhere by

TMC278 is Tibotec Pharmaceuticals’ investigational non-nucleoside reverse transcriptase inhibitor for HIV-1 infection in adults. Gilead previously submitted an NDA for the single-tablet regimen of Truvada/TMC278 on 23 November

Merge Healthcare claims its capabilities extend across all stages of clinical trials, international studies, and many clinical specialty trials. In addition to the customizable myEDC platform, the Merge